Cargando…

Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis

Convalescent plasma is a suggested treatment for Coronavirus disease 2019 (Covid-19), but its efficacy is uncertain. We aimed to evaluate whether the use of convalescent plasma is associated with improved clinical outcomes in patients with Covid-19.In this systematic review and meta-analysis, we sea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jorda, Anselm, Kussmann, Manuel, Kolenchery, Nebu, Siller-Matula, Jolanta M., Zeitlinger, Markus, Jilma, Bernd, Gelbenegger, Georg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859444/ https://www.ncbi.nlm.nih.gov/pubmed/35197981 http://dx.doi.org/10.3389/fimmu.2022.817829

Ejemplares similares

Anticoagulant Treatment Regimens in Patients With Covid‐19: A Meta‐Analysis
por: Jorda, Anselm, et al.
Publicado: (2021)

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups
por: Gelbenegger, Georg, et al.
Publicado: (2019)

Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Gager, Gloria M., et al.
Publicado: (2021)

Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta‐Analysis
por: Gelbenegger, Georg, et al.
Publicado: (2021)

Association Between the Expression of MicroRNA-125b and Survival in Patients With Acute Coronary Syndrome and Coronary Multivessel Disease
por: Gager, Gloria M., et al.
Publicado: (2022)

Calcium channel blockers reduce the antiplatelet effect of clopidogrel
por: Siller-Matula, Jolanta M, et al.
Publicado: (2008)

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A
por: Gelbenegger, Georg, et al.
Publicado: (2020)

Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antibacterial Agents: A Review
por: Jorda, Anselm, et al.
Publicado: (2020)

Interrupting methotrexate to improve immunity after COVID-19 booster vaccination: is it really worth it?
por: Jorda, Anselm, et al.
Publicado: (2022)

Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination
por: Gelbenegger, Georg, et al.
Publicado: (2021)

The efficiency of convalescent plasma in COVID-19 patients: A systematic review and meta-analysis of randomized controlled clinical trials
por: Qian, Zhenbei, et al.
Publicado: (2022)

Expression Patterns of MiR-125a and MiR-223 and Their Association with Diabetes Mellitus and Survival in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome
por: Gager, Gloria M., et al.
Publicado: (2023)

Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment
por: Ouyang, Jing, et al.
Publicado: (2020)

Effect of the human endotoxin challenge on tedizolid tissue penetration
por: Jorda, Anselm, et al.
Publicado: (2022)

Interplay between Genetic and Clinical Variables Affecting Platelet Reactivity and Cardiac Adverse Events in Patients Undergoing Percutaneous Coronary Intervention
por: Siller-Matula, Jolanta M., et al.
Publicado: (2014)

Cytokine levels associated with favorable clinical outcome in the CAPSID randomized trial of convalescent plasma in patients with severe COVID-19
por: Körper, Sixten, et al.
Publicado: (2022)

Prasugrel in critically ill patients
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials?
por: Jasiewicz, Małgorzata, et al.
Publicado: (2023)

Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19
por: Van Damme, Karel F. A., et al.
Publicado: (2020)

Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion
por: Wirz, Oliver F., et al.
Publicado: (2021)

Editorial: Updates on convalescent plasma and monoclonal antibody therapies for infectious disease in patients with primary immunodeficiency
por: Condino-Neto, Antonio, et al.
Publicado: (2022)

Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology
por: Cognasse, Fabrice, et al.
Publicado: (2022)

Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment
por: Wu, Jian, et al.
Publicado: (2021)

Ticagrelor and prasugrel are independent predictors of improved long‐term survival in ACS patients
por: Gager, Gloria M., et al.
Publicado: (2020)

Editorial: Antithrombotic Treatment in Transcatheter Structural Cardiac Interventions and After Cardiac Device Implantation
por: Siller-Matula, Jolanta M., et al.
Publicado: (2020)

Convalescent plasma and all-cause mortality of COVID-19 patients: systematic review and meta-analysis
por: Mihalek, Nora, et al.
Publicado: (2023)

The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial
por: Kovacevic, Katarina D., et al.
Publicado: (2021)

Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure
por: Keitel, Verena, et al.
Publicado: (2021)

Convalescent Plasma in the Treatment of Severe COVID-19: A Systematic Review and Meta-Analysis
por: ZHANG, Xuanguo, et al.
Publicado: (2020)

High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients
por: Greenbaum, Uri, et al.
Publicado: (2021)

Neutralization effect of plasma from vaccinated COVID-19 convalescents on SARS-CoV-2 Omicron variants
por: Xie, Yudi, et al.
Publicado: (2022)

Colistin dampens fibrinolysis and endothelial activation during endotoxaemia: A randomised, double blind trial
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

A pilot study for treatment of severe COVID-19 pneumonia by aerosolized formulation of convalescent human immune plasma exosomes (ChipEXO™)
por: Gül, Fethi, et al.
Publicado: (2022)

Clopidogrel in Critically Ill Patients
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma
por: Gilchuk, Pavlo, et al.
Publicado: (2021)

Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2
por: Taşlı, Neslihan Pakize, et al.
Publicado: (2022)

Associations Between Symptoms, Donor Characteristics and IgG Antibody Response in 2082 COVID-19 Convalescent Plasma Donors
por: Vinkenoog, Marieke, et al.
Publicado: (2022)

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
por: Senefeld, Jonathon W., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8ck7ejdn245jt49us2ge6n753m